SCHEMBL2408417

SCHEMBL2408417

CC(N)OB(c1cc(Cl)ccc1F)c1cc(Cl)ccc1F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.38
TP53 P04637 1/20 0.38
HTT P42858 1/20 0.38
ADRB2 P07550 1/20 0.34
HTR2A P28223 4/20 0.33
PNMT P11086 1/20 0.33
HTR2C P28335 2/20 0.32
HTR2B P41595 1/20 0.32
SLC6A2 P23975 1/20 0.32
SLC6A3 Q01959 1/20 0.32
CNR1 P21554 1/20 0.32
PSEN1 P49768 1/20 0.31
PSEN2 P49810 1/20 0.31
APH1B Q8WW43 1/20 0.31
NCSTN Q92542 1/20 0.31
APH1A Q96BI3 1/20 0.31
PSENEN Q9NZ42 1/20 0.31
HTR1A P08908 1/20 0.31
DRD2 P14416 1/20 0.31
HTR7 P34969 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2405775 0.80 SLC6A4 (0.35) HTR2AHTR2CSLC6A2PSEN1PSEN2
SCHEMBL2406878 0.71 HTR2A (0.33) LMNATP53HTTHTR2APNMT
SCHEMBL2408418 0.70 KDM4E (0.43) HTR2AHTR2CHTR2B
SCHEMBL31208432 0.69 ENPP2 (0.42) LMNATP53
SCHEMBL246398 0.69 ENPP2 (0.42) LMNATP53
SCHEMBL2407195 0.67
SCHEMBL19627773 0.66 LMNA (0.61) LMNATP53HTTADRB2PNMT
SCHEMBL20238511 0.66 LMNA (0.61) LMNATP53HTTADRB2PNMT
SCHEMBL19634066 0.66 LMNA (0.61) LMNATP53HTTADRB2PNMT
SCHEMBL2405776 0.66 SLC6A4 (0.39) LMNAHTTHTR2ASLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853424-B2 Protein cross-linking inhibitor JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2014-10-07 US disclosed
US-20110212919-A1 PROTEIN CROSS-LINKING INHIBITOR JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2011-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110212919-A1 PROTEIN CROSS-LINKING INHIBITOR BAZ2B, PRMT1, BRIX1 LMNA 3426/4885TP53 3913/4885HTT 3376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.